Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1R | P00736 | 15/20 | 1.00 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332595 | 0.84 | C1R (1.00) | C1RNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3453097 | 0.81 | C1R (0.71) | C1RF7F3NPC1RAB9A | |
| SCHEMBL7336273 | 0.79 | C1R (1.00) | C1RNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7329344 | 0.78 | C1R (1.00) | C1RF7F3NPC1RAB9A | |
| SCHEMBL3452889 | 0.75 | C1R (0.65) | C1RF7F3NPC1RAB9A | |
| SCHEMBL6506326 | 0.74 | C1R (0.70) | C1RNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3452111 | 0.73 | NPC1 (0.71) | C1RNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6229437 | 0.73 | ELANE (0.63) | C1RNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3452527 | 0.71 | ELANE (0.74) | C1RNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL915758 | 0.70 | F7 (1.00) | C1RF7F3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5652237-A | 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes | WARNER-LAMBERT COMPANY (US) | 1997-07-29 | — | — | US | disclosed |